Skip to main content
OpenTrials
Completed

NCT Number: NCT01792960

Registry and Prevalence of Gene Mutation in Korean Patients With Familial Hypertrophic Cardiomyopathy

Set the Korean Familial Hypertrophic Cardiomyopathy (KFHC) registry to study the prevalence of gene mutations in Korean patients with familial hypertrophic cardiomyopathy

Completed

Looking for future studies?

Notify Me

Key information

Age range

13 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Division of Cardiology, Severance Cardiovascular Hospital, Yonsei University College of Medicine

Seoul, 120-752, South Korea

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • left ventricular maximal wall thickness ≥ 15mm on echocardiography
  • hypertrophic cardiomyopathy patients' relatives

Exclusion criteria

  • other cardiomyopathy or systemic disease (e.g. fabry disease, danon disease, glycogen storage disease)
  • who deny the study entrance, especially in patients' relatives

Treatment and study plan

Primary outcomes

  1. 1) DNA analysis

    Time frame: 1 year

    • Identify susceptible genes for familial hypertrophic cardiomyopathy in Korean

Secondary outcomes

  1. 2) Prognosis of familial hypertrophic cariomyopathy

    Time frame: 1 year

    • all-cause mortality, hospitalization for heart failure progression, stroke, heart transplantation

Sponsors and collaborators

Lead sponsor

Yonsei University

Other

Registry information

Important dates

Study start
2013
Primary completion
2013
Study completion
2013
First posted
Feb 15, 2013
Registry last updated
Feb 19, 2014

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.